Publication

CCR East •
1 May, 2026 •
•

Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Edward M. Behrens, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullman, Adnan Mahmood, Andrew Danquah, Elena Burillo, Steve Mallett, Brian D. Jamieson, Alexei A. Grom, Fabrizio De Benedetti

Available materials

Poster

Publication

CCR East •
1 May, 2026 •
•

Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Alexei A. Grom, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Edward M. Behrens, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullman, Adnan Mahmood, Andrew Danquah, Elena Burillo, Steve Mallett, Brian D. Jamieson, Fabrizio De Benedetti

Available materials

Poster

Publication

CCR East •
1 May, 2026 •
•

Comparison of Diagnostic Journey and Utilization of Clinical Care Resources in Uncontrolled vs. Controlled Gout in the United States

Jigar Shah, Menaka Bhor, James Hawthorne, Nathan Meyer, Emily Goddard, Molly Edwards, Alastair Hinds, John A. Albert

Available materials

Poster

Publication

Efficacy and Safety of Emapalumab in Patients with Macrophage Activation Syndrome (MAS) in Systemic Lupus Erythematosus (SLE)

Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Comparison of Diagnostic Journey and Utilization of Clinical Care Resources in Uncontrolled vs. Controlled Gout in the United States

Association Between Clinical Manifestations of Gout and Patient Reported Outcome Measures: Results of a Real-World Survey in the United States

Nanoencapsulated Sirolimus Plus Pegadricase (NASP) Provides a Sustained 48-Week Response, Reducing Serum Uric Acid and Preserving Renal Function in Patients With Uncontrolled Gout (UG) and Stage 3 Chronic Kidney Disease

Treatment Patterns and Clinical Outcomes in Patients with both Uncontrolled Gout and Chronic Kidney Disease

Efficacy and Safety of Emapalumab in Patients with Macrophage Activation Syndrome (MAS) in Systemic Lupus Erythematosus (SLE)